Prasinezumab (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names NEOD002, PRX-002, RG-7935, RO-7046015) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which is under development for the treatment of Parkinson's disease. No significant effect on disease progression was seen in a 52-week phase 2 clinical trial. In any case, the trial was extended and development of the drug continues. There have been concerns about research misconduct and data fabrication relevant to prasinezumab. As of May 2024, prasinezumab is in phase 2 clinical trials for Parkinson's disease. It is under development by Prothena Biosciences and Roche.

See also

  • Cinpanemab

References

External links

  • Prasinezumab - AlzForum



Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But

Inefficacia di Prasinezumab nel Parkinson in stadio iniziale

Monoclonal antibody Prasinezumab slows progression of Parkinson's disease

(PDF) A Phase II study to evaluate the safety and efficacy of

Lungenkrebs Pralsetinib im Handel PZ Pharmazeutische Zeitung